Skip to content

The predictive ability of circulating tumor cell fth1 expression on the efficacy and prognosis of neoadjuvant therapy in patients with early breast cancer

The predictive ability of circulating tumor cell fth1 expression on the efficacy and prognosis of neoadjuvant therapy in patients with early breast cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046262
Enrollment
Unknown
Registered
2021-05-12
Start date
2021-05-12
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

case series:No

Sponsors

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Aged = 55%; 7. AST and ALT= 3.0x10^9 /L, neutrophils >=1.5x10^9 /L;Platelet count >= 100x10^9 /L; Hemoglobin >=90 g/L; 9. Able to understand the research process, participate in the study voluntarily, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. A history of other malignant tumors except breast cancer in the past 5 years; 2. Metastatic breast cancer indicated by imaging or pathology; 3. Uncontrolled pleural effusion, pericardial effusion, ascites; 4. Patients with severe heart disease or discomfort who are expected to be unable to tolerate chemotherapy, including but not limited to: (1)Fatal arrhythmias or higher grade atrioventricular block; (2)Valvular heart disease of clinical significance; (3)The electrocardiogram shows a transmural myocardial infarction; (4)Uncontrollable high blood pressure. 5. The investigator considers that the patient has any other condition that is not suitable for the study.

Design outcomes

Primary

MeasureTime frame
Pathological complete response rate;

Secondary

MeasureTime frame
Number of different types of circulating tumor cells;Expression of FTH1 in different types of circulating tumor cells;

Countries

China

Contacts

Public ContactGong Chang

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

changgong282@163.com+86 13925099353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026